Cavity development: a potential biomarker for antiangiogenesis agents.
作者信息
Jiang Man, Zhang Xiaochun
机构信息
Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266003, China.
出版信息
Transl Lung Cancer Res. 2020 Feb;9(1):156-157. doi: 10.21037/tlcr.2019.12.11.
Abstract
摘要
相似文献
1
Cavity development: a potential biomarker for antiangiogenesis agents.空洞形成：抗血管生成药物的一种潜在生物标志物。
Transl Lung Cancer Res. 2020 Feb;9(1):156-157. doi: 10.21037/tlcr.2019.12.11.
2
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.肺癌患者使用抗血管生成药物治疗期间的肿瘤空洞形成
J Thorac Oncol. 2008 Apr;3(4):351-7. doi: 10.1097/JTO.0b013e318168c7e9.
3
Molecular predictors of response to antiangiogenesis therapies.抗血管生成治疗反应的分子预测因子。
Cancer J. 2011 Mar-Apr;17(2):134-41. doi: 10.1097/PPO.0b013e318212db3c.
4
Antiangiogenesis: the fifth cancer treatment modality?抗血管生成：癌症治疗的第五种模式？
Oncol Nurs Forum. 2003 Nov-Dec;30(6):934-44. doi: 10.1188/03.ONF.934-944.
5
Targeted antiangiogenesis gene therapy using targeted cationic microbubbles conjugated with CD105 antibody compared with untargeted cationic and neutral microbubbles.与非靶向阳离子微泡和中性微泡相比，使用与CD105抗体偶联的靶向阳离子微泡进行靶向抗血管生成基因治疗。
Theranostics. 2015 Feb 1;5(4):399-417. doi: 10.7150/thno.10351. eCollection 2015.
6
The antitumour growth and antiangiogenesis effects of xanthatin in murine glioma dynamically evaluated by dynamic contrast-enhanced magnetic resonance imaging.动态对比增强磁共振成像动态评价莪术呋喃二酮对小鼠脑胶质瘤的抗肿瘤生长和抗血管生成作用。
Phytother Res. 2019 Jan;33(1):149-158. doi: 10.1002/ptr.6207. Epub 2018 Oct 22.
7
Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer.可溶性 VEGFR-1 在癌症抗血管生成治疗中的潜在作用。
Expert Rev Anticancer Ther. 2011 Apr;11(4):541-9. doi: 10.1586/era.10.171.
8
Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.血管抑素和苏拉明抗血管生成的不同方式以及血管抑素诱导抗血管生成的定量分析
APMIS. 2007 Jan;115(1):30-46. doi: 10.1111/j.1600-0463.2007.apm_405.x.
9
In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel antiangiogenesis agent.多甲氧基黄酮的体外和体内结构-活性关系分析：鉴定橙皮素为一种新型血管生成抑制剂。
Mol Nutr Food Res. 2012 Jun;56(6):945-56. doi: 10.1002/mnfr.201100680.
10
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.人参皂苷Rg3与低剂量节拍性替莫唑胺对大鼠胶质瘤细胞的体内外联合抗血管生成作用。
J Exp Clin Cancer Res. 2016 Feb 13;35:32. doi: 10.1186/s13046-015-0274-y.
本文引用的文献
1
Lung cavitation in lung metastases of gastric and non-small-cell lung cancer patients treated with apatinib.阿帕替尼治疗的胃癌和非小细胞肺癌患者肺转移中的肺空洞形成
Transl Lung Cancer Res. 2019 Aug;8(4):317-318. doi: 10.21037/tlcr.2019.08.20.
2
Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?肺空洞形成对抗血管生成治疗的影响及机制：空洞形成是新的注意事项吗？
Transl Lung Cancer Res. 2019 Aug;8(4):319-322. doi: 10.21037/tlcr.2019.08.19.
3
Influence and mechanism of lung cavitation development on antiangiogenic therapy.肺空洞形成对抗血管生成治疗的影响及机制
Transl Lung Cancer Res. 2019 Aug;8(4):500-512. doi: 10.21037/tlcr.2019.07.01.
4
Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.血管抑制剂恩度诱导晚期非小细胞肺癌患者肿瘤空洞的发生率及其临床意义。
Thorac Cancer. 2014 Sep;5(5):438-46. doi: 10.1111/1759-7714.12115. Epub 2014 Aug 25.
5
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.贝伐珠单抗抗血管生成治疗非小细胞肺癌患者的瘤腔空洞。
Cancer Imaging. 2012 Jun 29;12(1):225-35. doi: 10.1102/1470-7330.2012.0027.
6
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.肿瘤空洞形成：对非小细胞肺癌血管生成抑制剂试验中客观缓解评估的影响
J Clin Oncol. 2009 Jan 20;27(3):404-10. doi: 10.1200/JCO.2008.16.2545. Epub 2008 Dec 1.
7
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.肺癌患者使用抗血管生成药物治疗期间的肿瘤空洞形成
J Thorac Oncol. 2008 Apr;3(4):351-7. doi: 10.1097/JTO.0b013e318168c7e9.
Zotero 插件